Emerg Infect Dis by Meyer, Benjamin et al.
Serologic Assessment  
of Possibility for MERS-CoV 
Infection in Equids
Benjamin Meyer, Ignacio García-Bocanegra, 
Ulrich Wernery, Renate Wernery, Andrea Sieberg, 
Marcel A. Müller, Jan Felix Drexler,  
Christian Drosten, and Isabella Eckerle
Author affiliations: University of Bonn Medical Centre, Bonn,  
Germany (B. Meyer, A. Sieberg, M.A. Müller, C. Drosten, J.F.  
Drexler, I. Eckerle); Universidad de Córdoba, Córdoba, Spain  
(I. García-Bocanegra); and Central Veterinary Research  
Laboratory, Dubai, United Arab Emirates (U. Wernery, R. Wernery)
DOI: http://dx.doi.org/10.3201/eid2101.141342
To the Editor: In 2012, a novel coronavirus termed 
Middle East respiratory syndrome coronavirus (MERS-
CoV) emerged on the Arabian Peninsula; the virus has been 
responsible for >800 human cases. Recently, evidence of 
MERS-CoV infection in dromedaries was obtained from 
the Canary Islands, the Arabian Peninsula, and Africa (1–
3). Viral sequences from dromedaries and from humans 
infected with MERS-CoV were highly similar, suggesting 
a prominent role of dromedaries as an animal reservoir of 
the virus (4). However, the serologic assessment of other 
animal species has been incomplete. Investigations of do-
mestic animal species have been restricted to goats, sheep, 
and cattle (3) and a limited study of horses (n = 3) (5). No 
evidence of recent infection was found in either study.
Whereas most known CoVs have a highly restricted 
host range in vitro and in vivo, MERS-CoV has been found 
to infect a broad range of cell cultures derived from Old 
and New World camelids as well as humans, primates, 
bats, pigs, and goats (6). MERS-CoV uses the receptor di-
peptidyl-peptidase-4 (DPP-4) to enter its host cell (7). Se-
quence comparison between the receptor-binding domain 
of the MERS-CoV spike protein and several mammalian 
DPP-4 sequences showed a higher percentage identity in 
the amino acid residues critical for virus entry between hu-
man and horse DPP-4 than between human and dromedary 
DPP-4 (8). It has been shown that MERS-CoV can use 
horse DPP-4 expressed on nonsusceptible cells (9), but no 
data are available on susceptibility of primary horse cells. 
Therefore, members of the family Equidae, which include 
domestic horses, donkeys, and mules, might be susceptible 
to MERS-CoV infection. According to the Food and Agri-
cultural Organization of the United Nations (http://faostat.
fao.org), >800,000 equids (horses, mules, and donkeys) are 
present on the Arabian Peninsula, but their role as putative 
MERS-CoV animal reservoirs has not been investigated. 
Therefore, we assessed in vitro susceptibility of primary 
horse cells to MERS-CoV infection and searched for se-
rologic evidence of infection with MERS-CoV in equids 
originating from Spain and the United Arab Emirates.
Primary cells derived from the kidney of 2 horses 
(termed PN-R and PFN-R) and an interferon-deficient pri-
mate cell line (VeroB4) were infected with MERS-CoV 
at a multiplicity of infection of 0.5 PFUs. Virus replica-
tion was quantified by real-time reverse transcription PCR 
(MERS-CoV upE assay) (10) and by plaque assay in Vero 
cells to confirm the production of infectious virus particles. 
Both cell lines showed clear cytopathic effects, an increase 
of viral RNA, and production of infectious virus progeny 
(Figure, panels A, B).
To investigate equids for signs of infection with MERS-
CoV, we collected 1,053 serum samples from MERS-CoV–
endemic and –nonendemic areas: 192 samples from adult 
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Figure. Analysis of the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) in primary horse kidney cell lines and 
origin of equine serum samples. A, B) Cells were seeded at densities of 2 × 105 cells/mL and infected in triplicate with a multiplicity of 
infection of 0.5 infectious MERS-CoV units/cell. After incubation for 1 h, cells were washed twice and supernatants were harvested at 
0, 20, and 40 h postinfection (hpi). The replication level is given as the log of the genome equivalents (A) or as PFUs (B). Error bars 
indicate SDs; PF-N and PFN-R indicate the 2 primary horse cell lines; VeroB4 is an interferon-deficient primate cell line. C) Distribution 
of optical density (OD) values (450 nm) of equine serum samples originating from Spain or the United Arab Emirates (UAE).
endurance horses from the United Arab Emirates that were 
collected for routine veterinary purposes; and 861 samples 
from 697 horses, 82 donkeys, and 82 mules in Spain. Be-
cause the reactivity of equid serum against MERS-CoV has 
not been investigated, we established a 2-stage algorithm for 
serologic testing that did not involve the determination of re-
activity cutoff values. The screening stage involved testing 
of all serum samples by using a previously described ELISA 
with the spike protein S1-domain of MERS-CoV as the test 
antigen (4). The ELISA was adapted for use with horse se-
rum by exchange of the secondary antibody. All serum sam-
ples reacted with low to medium OD values (range 0.0–0.55) 
(Figure, panel C). We then tested the 50 most reactive serum 
samples (optical density range 0.22–0.55) by using recombi-
nant immunofluorescent and microneutralization assays (1). 
These assays are more specific than the ELISA assay and 
therefore can be used for confirmation. None of the tested 
serum samples showed reactivity in the recombinant immu-
nofluorescent or microneutralization assays; this finding sug-
gests that no previous exposure of equids to MERS-CoV has 
occurred in the United Arab Emirates and Spain.
Identifying all potential animal reservoirs is a critical 
step in controlling zoonotic diseases. Molecular data sug-
gest that horses may be highly susceptible to MERS-CoV 
because of their high similarity in DPP-4 amino acids at po-
sitions critical for binding of the MERS-CoV spike protein 
(8). Our in vitro data confirm the susceptibility of primary 
horse cells, showing production not only of viral RNA but 
also of infectious virus progeny, which is a prerequisite for 
transmission. The lower replication observed in horse cells 
than in VeroB4 cells may be the result of a difference in the 
interferon competence of the cells; replication levels in horse 
cells are comparable to those in bat cells (6). Although we 
did not find evidence for equid infections with MERS-CoV 
in this study, the general susceptibility on the cell culture 
level suggests that equids from MERS-CoV–endemic areas, 
such as Africa and the Arabian Peninsula, should be further 
investigated for possible infection with MERS-CoV.
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To the Editor: Dengue fever, a mosquito-borne dis-
ease caused by dengue virus, can be asymptomatic or re-
sult in a variety of clinical manifestations, including fever, 
headache, myalgia, arthralgia, and rash (1). Severe cases 
can cause shock or severe hemorrhage (1). During the 
past 50 years, dengue has become a public health concern 
worldwide, rapidly spreading geographically, mainly in 
tropical and subtropical countries (1).
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